Gene Therapy Haemophilia B Scottish Medicines Consortium

Gene Therapy for Haemophilia B to be licensed next year

A gene therapy for haemophilia B has moved a step closer to being licensed for use in the UK. On Friday, the CHMP has announced a positive opinion for EtranaDez (Etranacogene Dezaparvovec) which will be marketed as Hemgenix. This product was developed by Uniqure and will be marketed by CSL Behring.

The Haemophilia Society have released a statement on this which you can read on their website.

Although their statement pertains to the NHS in England, we expect similar considerations to take place in Scotland on whether the Scottish Medicines Consortium (SMC) will recommend the treatment for use in Scotland. We will keep our members updated on any developments.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: